A recent study found that being taller in adolescence, as well as losing and gaining weight multiple times, is associated with increased ovarian cancer risk and mortality.

News

A recent study found that treatment with PARP inhibitors significantly increases the risk of hematologic toxicities and warrants frequent clinical monitoring by clinicians.

Read More

The Institute for Clinical and Economic Review (ICER) confirmed in a recent report that evidence is lacking for outcomes comparisons of ploy-ADP ribose polymerase (PARP) inhibitors to treat ovarian cancer, and that prices should be lowered to increase affordability and patient access.

Read More

A recent study assessed the hypothesis that prolonging the platinum-free interval with platinum-free chemotherapy may offer improved outcomes in patients with progressing ovarian cancer, published in the Journal of Clinical Oncology (October 2017;35[29]:3347-3353).

Read More

Patients with ovarian cancer who are responsive to platinum-based chemotherapy may experience more than double an increase in progression-free survival (PFS) with a specific maintenance therapy, regardless of their disease characterization.

Read More

Research in Review

A combination regimen involving standard carboplatin chemotherapy and a novel drug may improve overall survival for more than 50% of women with high-grade serous ovarian cancers, according to research published in Precision Oncology (published online May 2017; doi:10.1038/s41698-017-0008-z).

-----

Related Content

Read More

Common comorbidities such as hypertension, heart disease, and diabetes may contribute to a woman’s prognosis after being diagnosed with ovarian cancer, according to a study published in Cancer Causes Control (2017;28[5]:469-486).

-----

Related Content

Read More

Women with stage II-IV low-grade serous carcinoma of the ovary or peritoneum who received hormonal maintenance therapy after primary treatment had longer progression-free survival (PFS) compared with women who underwent routine observation after primary treatment.
-----
Related Content

Read More

Primary cytoreductive surgery (PCS) is better than neoadjuvant chemotherapy (NACT) for overall survival in women aged 70 years or younger with advanced-stage epithelial ovarian cancer (EOC), according to a recent study published in JAMA Oncology.

-----

Related Content

Read More

Subscribe to Ovarian Cancer